Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oncolix, Inc.oncx · Entity 165137 | Director | June 26, 2018 | July 09, 2018 |
| PetVivo Holdings, Inc.PETV · Entity 7591 | Director | January 15, 2019 | February 21, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oncolix, Inc.
Report date June 26, 2018 · Filed July 09, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock Purchase OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2021-06-26 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-06-26 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Options to purchase 1,000,000 shares of common stock were granted on June 26, 2018 with 333,333 vesting upon election to the Board, 333,333 vesting upon the first anniversary of election and 333,333 vesting upon the second anniversary of election. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase 1,000,000 shares of common stock were granted on June 26, 2018 with 333,333 vesting upon election to the Board, 333,333 vesting upon the first anniversary of election and 333,333 vesting upon the second anniversary of election.
PetVivo Holdings, Inc.
Report date January 15, 2019 · Filed February 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2029-01-15 | Direct | 287,750 |
Reported balance
After 2019-01-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-15 · Grant · Acquired 187,750 · Balance 287,750 F1: On January 15th, 2019, the Company's Board of Directors approved the issuance of 187,750 warrants for purchase of common stock to Sherry Grisewood, vested immediately, for a term of ten years with a strike price of $.30 per share and a one-time protection against a reverse split whereby the strike price will not be adjusted upon combination of outstanding shares of stock; this warrant was issued for increased participation in Company activities above what is expected for a Director of the Board. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 15th, 2019, the Company's Board of Directors approved the issuance of 187,750 warrants for purchase of common stock to Sherry Grisewood, vested immediately, for a term of ten years with a strike price of $.30 per share and a one-time protection against a reverse split whereby the strike price will not be adjusted upon combination of outstanding shares of stock; this warrant was issued for increased participation in Company activities above what is expected for a Director of the Board.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Marker Therapeutics, Inc.
Report date October 16, 2018 · Filed October 17, 2018
Section 16 reporting ended · disclosed 2018-10-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,582 |
Reported balance
After 2018-10-16 transaction · row 1
1 source rowRow 1 · 2018-10-16 · Grant · Acquired 4,106 · Balance 19,582 F1: Represents the pro-rated portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $7.74 per share, on the day immediately preceding the date of the Company's 20178annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the pro-rated portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $7.74 per share, on the day immediately preceding the date of the Company's 20178annual meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2019 Filed Feb 21, 2019 18:11 UTC | PetVivo Holdings, Inc. PETV · Entity 7591 | GrantCommon Stock Warrant · Derivative | 187,750 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001493152-19-002346 · ownership.xml · derivative · entry 1 Grisewood Sherry · CIK 0001658039 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,750 Underlying: Common Stock · 187,750 shares Expires 2029-01-15 F1 · price: On January 15th, 2019, the Company's Board of Directors approved the issuance of 187,750 warrants for purchase of common stock to Sherry Grisewood, vested immediately, for a term of ten years with a strike price of $.30 per share and a one-time protection against a reverse split whereby the strike price will not be adjusted upon combination of outstanding shares of stock; this warrant was issued for increased participation in Company activities above what is expected for a Director of the Board. Read SEC document |
| October 16, 2018 Filed Oct 17, 2018 12:52 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | GrantCommon Stock | 4,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-054107 · tv504935_4.xml · nonDerivative · entry 1 Grisewood Sherry · CIK 0001658039 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,582 F1 · shares: Represents the pro-rated portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $7.74 per share, on the day immediately preceding the date of the Company's 20178annual meeting. Read SEC document |
| August 29, 2017 Filed Aug 30, 2017 20:02 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | GrantCommon Stock | 13,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-045903 · v474356_4.xml · nonDerivative · entry 1 Grisewood Sherry · CIK 0001658039 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,476 F1 · shares: Represents the portion of the annual retainer for each non-employee director payable in immediately vested restricted, common stock under the Company's 2014 Omnibus Stock Ownership Plan and based on the closing price of $3.05 per share, on the day immediately preceding the date of the Company's 2017 annual meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.